Viatris Q1 revenue up 8% to $3.5B; launches $700-850M restructuring, sells Biocon stake

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Company launched enterprise-wide restructuring targeting up to 10% workforce reduction, with $700-850M in charges over three years and expected savings of $600-700M once implemented. Q1 2026 recognized $77.9M in restructuring costs.

  MD&A: 2026 Restructuring Program verify on EDGAR →
• high

  Sold entire Biocon Biologics stake for $815M ($400M cash, $415M Biocon equity with six-month lockup), closing in Q1 2026. Transaction accelerates expiration of biosimilars non-compete restrictions to November 2026 for U.S. market.

  MD&A: Biocon Biologics Divestiture verify on EDGAR →
• high

  Fire at Nashik, India manufacturing facility in mid-February caused $71.9M in Q1 charges and temporary suspension of operations. Full operations expected to resume July 2026; company believes it has insurance coverage but warns of potential negative impact if restoration fails.

  MD&A: Nashik Facility Fire verify on EDGAR →